Sysmex Corporation TSE:6869
Sysmex : Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2026
Source: MarketScreener
February 12, 2026
Listed company name : Sysmex Corporation
Code : 6869
Listed stock exchanges : Tokyo Stock Exchange
URL : https://www.sysmex.co.jp/en
Company representative : Kaoru Asano, President
Contact : Takuro Minami, Executive Vice President of Corporate Business Administration
Phone : 078(265)-0500
Scheduled date for dividend payment : -
Preparation of supplementary material for quarterly earnings
: Yes
Holding of earnings announcement : Yes
(Unit: Millions of Yen)
-
Results for the First Nine Months of the Fiscal Year Ending March 31, 2026
Operating results
(% changes as compared with the corresponding period of the previous fiscal year)
Net Sales
Operating profit
Profit before tax
Profit
Nine months ended Dec. 31, 2025
Nine months ended
Dec. 31, 2024
361,168
366,866
(1.6)%
12.4%
48,657
67,345
(27.7)%
24.2%
47,471
61,792
(23.2)%
20.9%
33,522
42,497
(21.1)%
23.2%
Profit attributable
to owners of the parent
Total
comprehensive income
Basic earnings per
share (Yen)
Diluted earnings per
share (Yen)
Nine months ended Dec. 31, 2025
33,694
(20.9)%
60,121
23.7%
54.05
54.05
Nine months ended Dec. 31, 2024
42,615
23.7%
48,586
1.9%
68.35
68.33
Financial condition
Total assets
Total equity
Equity attributable to owners of the
parent
Equity attributable to owners of the
parent to total assets
As of Dec. 31, 2025
698,249
501,429
500,842
71.7%
As of Mar. 31, 2025
665,268
464,534
463,776
69.7%
-
Dividend
Dividend per share
First quarter
(Yen)
Second quarter
(Yen)
Third quarter
(Yen)
Year-end
(Yen)
Annual
(Yen)
Year ended Mar. 31, 2025
Year ending Mar. 31, 2026
￣
15.00
￣
17.00
32.00
￣
19.00
￣
Year ending Mar. 31, 2026
(Forecast)
19.00
38.00
Notes: 1. Revision of dividends forecast for this period: No
2. Details of the dividends for the fiscal year ending March 31, 2026 Second quarter Ordinary dividend: ¥18.00
Commemorative dividend: ¥1.00 (30th anniversary of listing) Year-end Ordinary dividend: ¥18.00
Commemorative dividend: ¥1.00 (30th anniversary of listing)
-
Financial Forecast for the Year Ending March 31, 2026
(% changes as compared with the previous fiscal year)
Net Sales
Operating profit
Profit before tax
Profit attributable to
owners of the parent
Basic earnings
per share (Yen)
Year ending
Mar. 31, 2026
500,000
(1.7)%
62,000
(29.2)%
59,000
(25.5)%
41,000
(23.6)%
65.77
Note: Revision of financial forecast for this period: Yes
- Other Information
Significant changes in scope of consolidation: No
Changes in accounting policies and accounting estimates
Changes in accounting policies required by IFRS: No
Other changes in accounting policies: No
Changes in accounting estimates: No
Number of outstanding stock (common stock)
Number of outstanding stock at the end of each fiscal period (including treasury stock): 629,480,076 shares as of Dec. 31, 2025; 629,473,176 shares as of Mar. 31, 2025
Number of treasury stock at the end of each fiscal period:
6,300,045 shares as of Dec. 31, 2025; 5,873,371 shares as of Mar. 31, 2025
Average number of outstanding stock for each period (cumulative):
623,393,669 shares for the nine months ended Dec. 31, 2025 623,514,070 shares for the nine months ended Dec. 31, 2024
Note: The Company has introduced Executive Compensation BIP Trust and Stock-Granting Employee Stock Ownership Plan (ESOP) Trust. Company shares held by the trust are included in treasury stock and are excluded from calculations of the number of treasury stock at the end of the fiscal period and the average number of outstanding stock for the period.
Review of the accompanying quarterly consolidated financial statements by a certified public accountant or auditing firm: Yes (optional)
Explanation regarding the appropriate use of financial forecast and other information
The forecasts and future projections contained herein have been prepared on the basis of rational decisions given the information available as of the date of announcement of this document. These forecasts do not represent a commitment by the Company, and actual performance may differ substantially from forecasts for a variety of reasons. Please refer to "3) Consolidated financial forecast" within "1. Qualitative information on quarterly financial results" on page 4 of the attachment to this document for cautionary statements concerning the conditions and performance forecasts that serve as the basis for these forecasts.
Supplementary financial materials (in Japanese and English) will be posted on the Sysmex website on Thursday, February 12, 2026.
Qualitative information on quarterly financial results 2
Operating performance analysis 2
Financial conditions analysis 3
Consolidated financial forecast 4
Operating risks 4
Business and financial issues to be addressed 4
Important management contracts, etc. 4
Condensed quarterly consolidated financial statements and notes 5
Condensed quarterly consolidated statement of financial position 5
Condensed quarterly consolidated statement of income 7
Condensed quarterly consolidated statement of comprehensive income 8
Condensed quarterly consolidated statement of changes in equity 9
Condensed quarterly consolidated statement of cash flows 10
Notes to the condensed quarterly consolidated financial statements 11
Key considerations on the basis for the preparation of condensed quarterly consolidated 11
financial statements
Notes related to the going concern assumption 11
Segment information 11
-
Qualitative information on quarterly financial results
Future-related information contained in the text below is based on the Company's judgement as of
the end of the fiscal period under review.
Operating performance analysis
The Group's consolidated financial results for the first nine months of the fiscal year ending March 31, 2026 are as follows.
Net sales by destination
Nine months ended December 31, 2024
Nine months ended December 31, 2025
YoY (Previous period = 100)
Amount
(Millions of yen)
Percentage of
total (%)
Amount
(Millions of yen)
Percentage of
total (%)
Japan
47,190
12.9
40,509
11.2
85.8
Americas
96,425
26.3
100,829
27.9
104.6
EMEA
(Europe, the Middle East, and Africa)
102,871
28.0
114,909
31.8
111.7
China
82,000
22.3
65,533
18.2
79.9
AP (Asia Pacific)
38,378
10.5
39,386
10.9
102.6
Overseas subtotal
319,675
87.1
320,659
88.8
100.3
Total
366,866
100.0
361,168
100.0
98.4
In Japan, we experienced lower sales of hematology instruments and reagents, as well as immunochemistry reagents. As a result, sales in Japan fell 14.2% year on year, to ¥40,509 million, and the sales ratio decreased 1.7 percentage points, to 11.2%.
Overseas, sales of reagents in the hemostasis and immunochemistry fields decreased. However, instrument sales rose in the urinalysis and other fields. Accordingly, overseas sales rose 0.3%, to
¥320,659 million, and the overseas sales ratio increased 1.7 percentage points, to 88.8%.
Selling, general and administrative (SG&A) expenses totaled ¥120,206 million, up 9.3% year on year, due primarily to an increase in personnel associated with business expansion, as well as higher amortization expenses related to investments in digital infrastructure. R&D expenses came to
¥20,444 million, down 9.3%.
As a result, on a consolidated basis for the first nine months of the fiscal year ending March 31, 2026, net sales amounted to ¥361,168 million (down 1.6% year on year), operating profit was
¥48,657 million (down 27.7%), profit before tax was ¥47,471 million (down 23.2%), and profit attributable to owners of the parent totaled ¥33,694 million (down 20.9%).
Performance by segment
Headquarters
In South Korea, hematology instruments grew, but in Japan sales of hematology instruments and reagents decreased, as did sales of immunochemistry reagents. In the medical robotics business, sales of maintenance services grew, but sales of instruments decreased. Consequently, sales fell 8.9% year on year, to ¥60,580 million.
On the profit front, in addition to the decline in sales, a worsening cost of sales ratio and an increase in SG&A expenses led to a segment profit (operating profit) of ¥19,043 million (down 55.1%).
Americas RHQ
In North America, sales rose for hematology instruments and reagents, as well as for urinalysis instruments and maintenance services. In Central and South America, sales of urinalysis instruments and reagents increased. As a result, sales in the Americas were up 5.0% year on year, to ¥95,061 million.
On the profit front, higher sales and other factors pushed up segment profit (operating profit) 16.4% year on year, to ¥6,289 million.
EMEA RHQ
In the hematology field, sales of instruments and reagents grew, mainly in the region's key countries. Sales of instruments in the urinalysis and other fields also increased, bolstering sales for the region by 11.7% year on year, to ¥111,082 million.
Higher sales and an improved cost of sales ratio pushed up segment profit (operating profit) 13.5% year on year, to ¥8,864 million.
China RHQ
Operating in a difficult business environment affected by policies to curtail medical expenses, we experienced significant sales declines in hematology instruments and reagents, as well as hemostasis reagents. As a result, segment sales were ¥65,414 million, down 20.1% year on year.
Although lower SG&A expenses had a positive impact on profit, lower sales caused segment profit (operating profit) to fall 9.3% year on year, to ¥7,467 million.
Asia Pacific RHQ
Reagent sales increased in the hemostasis and urinalysis fields. In the hematology field, sales of instruments and maintenance services decreased, while reagent sales grew. Accordingly, sales expanded by 1.7%, to ¥29,027 million.
Despite the higher sales, segment profit (operating profit) decreased 16.5%, to ¥4,649 million, as the cost of sales ratio deteriorated owing to such factors as depreciation on our new production site in India, which was completed in August 2024.
Financial conditions analysis
Financial conditions
As of December 31, 2025, total assets amounted to ¥698,249 million, up ¥32,980 million from their level on March 31. Among major factors, cash and cash equivalents were down ¥13,809 million, whereas inventories increased by ¥17,555 million, property, plant and equipment by
¥14,632 million. Among non-current assets, trade and other receivables expanded ¥5,473 million.
Meanwhile, total liabilities decreased by ¥3,914 million from March 31, 2025, to ¥196,820 million. Key changes included a ¥6,647 million rise in non-current lease liabilities and ¥1,716 million higher contract liabilities. Meanwhile, income taxes payable declined by ¥8,591 million, and accrued bonuses by ¥4,516 million.
Total equity increased by ¥36,894 million from March 31, 2025, to ¥501,429 million. Among principal reasons, other components of equity increased ¥26,640 million and retained earnings increased ¥11,211 million. The equity attributable to owners of the parent to total assets rose 2.0 percentage points, from 69.7% as of March 31, 2025, to 71.7%.
Cash flows
As of December 31, 2025, cash and cash equivalents amounted to ¥75,760 million, down
¥13,809 million from March 31, 2025.
Cash flows from various activities during the first nine months of the fiscal year are described in more detail below.
(Cash flows from operating activities)
Net cash provided by operating activities was ¥50,044 million, down ¥8,878 million from the first nine months of the preceding fiscal year. As principal factors, profit before tax provided
¥47,471 million (¥14,321 million less than in the corresponding period of the preceding fiscal year), depreciation and amortization provided ¥34,820 million (up ¥6,119 million), a decrease in trade receivables provided ¥13,342 million (up ¥4,306 million), an increase in inventories used ¥12,602 million (up ¥210 million), and income taxes paid used ¥26,457 million (up ¥1,562 million).
(Cash flows from investing activities)
Net cash used in investing activities was ¥37,560 million (up ¥3,414 million). Among major factors, purchases of property, plant and equipment used ¥22,191 million (up ¥4,493 million), and purchases of intangible assets used ¥13,549 million (down ¥2,513 million).
(Cash flows from financing activities)
Net cash used in financing activities was ¥32,705 million (up ¥10,184 million). This was mainly